|
|
|
|
| LEADER |
02586nam a22004335i 4500 |
| 001 |
978-3-319-70142-4 |
| 003 |
DE-He213 |
| 005 |
20171204113727.0 |
| 007 |
cr nn 008mamaa |
| 008 |
171204s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319701424
|9 978-3-319-70142-4
|
| 024 |
7 |
|
|a 10.1007/978-3-319-70142-4
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Targeted Therapies in Breast Cancer
|h [electronic resource] /
|c edited by Jenifer R. Prosperi.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XV, 184 p. 12 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 16
|
| 505 |
0 |
|
|a Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
|
| 520 |
|
|
|a We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 700 |
1 |
|
|a Prosperi, Jenifer R.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319701417
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 16
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-70142-4
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
